Illumina and Regeneron are taking stakes in health data ... millions by analyzing the leftover specimens taken from routine lab tests. The goal is to build the most diverse database possible ...

DNA sequencing company Illumina and biotech Regeneron have invested in electronic ... held Truveta has a valuation exceeding $1bn. The new Truveta Genome Project initiative aims to generate ...

Regeneron disclosed the lawsuit—first filed in New York federal court in late November and amended the following month—Wednesday in its annual filing with the Securities and Exchange Commission.

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project ... from routine lab tests to sequence up ...

FSA Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals during the third quarter valued at $26,000. Fairfield Financial Advisors LTD bought a new stake in Regeneron ...

Regeneron believes there is $220bn of market share up for grabs - capturing just 5% of that would provide >$11bn of new revenues streams, but we ought to acknowledge that the competition in every ...

Positive results should put Regeneron on the map of investors looking for exposure to obesity. I wrote about these candidates in February 2024. New results from a proof-of-concept trial of ...

Facilities for Regeneron Canada in thriving Mississauga/GTA biotech hub signal its growth and readiness to bring more of its life-transforming innovative medicines for serious diseases to ...

The health care innovators behind the new Truveta Genome ... free to visit a partner lab without contributing to the project.) Your biospecimen will be sent to the Regeneron Genetics Center ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Rocket Lab launched five "Internet of Things" satellites on Saturday (Feb. 8). A 59-foot ...

Moments after Regeneron CEO Len Schleifer scolded analysts ... a first for the company—which “should help attract new investors to the name while not detracting from the company’s prevailing ...